Compare Neurocrine Biosciences Inc (NBIX) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs TransMedics Group Inc — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while TransMedics Group Inc trades at $74.3 (market cap $2.54B). The key difference: Neurocrine Biosciences Inc is far larger — about 6.9× TransMedics Group Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | TMDX | |
|---|---|---|
Market Cap | $17.40B | $2.54B |
Sector | Health | Technology |
52-Week High | $180.55 | $150.42 |
52-Week Low | $123.10 | $61.99 |
Enterprise Value | $16.49B | $2.94B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
